Aptose Biosciences (APTO) Downgraded to “Strong Sell” at ValuEngine
ValuEngine cut shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) from a sell rating to a strong sell rating in a report released on Friday morning.
Several other brokerages also recently commented on APTO. HC Wainwright set a $4.00 target price on Aptose Biosciences and gave the company a buy rating in a report on Wednesday, November 15th. Zacks Investment Research upgraded Aptose Biosciences from a hold rating to a buy rating and set a $2.00 target price on the stock in a report on Friday, November 17th. Canaccord Genuity set a $7.00 target price on Aptose Biosciences and gave the company a buy rating in a report on Wednesday, November 15th. Finally, Roth Capital reiterated a buy rating and set a $5.00 target price on shares of Aptose Biosciences in a report on Monday, October 23rd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the stock. The company presently has an average rating of Buy and an average price target of $4.50.
Shares of Aptose Biosciences (NASDAQ:APTO) traded down $0.02 during trading hours on Friday, hitting $2.01. The company had a trading volume of 312,144 shares, compared to its average volume of 413,148. Aptose Biosciences has a 1-year low of $0.78 and a 1-year high of $2.30.
ILLEGAL ACTIVITY NOTICE: This report was first published by Watch List News and is owned by of Watch List News. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at https://www.watchlistnews.com/aptose-biosciences-apto-downgraded-to-strong-sell-at-valuengine/1739858.html.
Aptose Biosciences Company Profile
Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.
Receive News & Ratings for Aptose Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.